Retinal toxicity after cisplatin-based chemotherapy in patients with germ cell cancer
Dulz S, Asselborn N, Dieckmann K, Matthies C, Wagner W, Weidmann J, Seidel C, Oing C, Berger L, Alsdorf W, Mankichian B, Meyer C, Vetterlein M, Gild P, Ludwig T, Soave A, Schriefer P, Becker A, Ahyai S, Oechsle K, Bokemeyer C, Wagenfeld L, Fisch M, Hartmann M, Chun F, Kluth L
J CANCER RES CLIN. 2017 [Epub ahead of print].

The marine triterpene glycoside frondoside A induces p53-independent apoptosis and inhibits autophagy in urothelial carcinoma cells
Dyshlovoy S, Madanchi R, Hauschild J, Otte K, Alsdorf W, Schumacher U, Kalinin V, Silchenko A, Avilov S, Honecker F, Stonik V, Bokemeyer C, von Amsberg G
BMC CANCER. 2017;17(1):93.

Cisplatin-refraktäre Keimzelltumoren: Resistenzmechanismen − Therapiestandards − neue Entwicklungen
Oing C, Seidel C, Alsdorf W, Bokemeyer C
ONKOLOGE. 2017;23(2):123-128.

Severe and irreversible myelopathy after concurrent systemic and intrathecal nucleoside analogue treatment for refractory diffuse large B-cell lymphoma: A case report and review of the literature
Alsdorf W, Schmitz M, Schieferdecker A, Dierlamm J, Bokemeyer C, Binder M
J Oncol Pharm Pract. 2016;22(3):523-7.

The marine triterpene glycoside frondoside A exhibits activity in vitro and in vivo in prostate cancer
Dyshlovoy S, Menchinskaya E, Venz S, Rast S, Amann K, Hauschild J, Otte K, Kalinin V, Silchenko A, Avilov S, Alsdorf W, Madanchi R, Bokemeyer C, Schumacher U, Walther R, Aminin D, Fedorov S, Shubina L, Stonik V, Balabanov S, Honecker F, von Amsberg G
INT J CANCER. 2016;138(10):2450-65.

Marine compound rhizochalinin shows high in vitro and in vivo efficacy in castration resistant prostate cancer
Dyshlovoy S, Otte K, Alsdorf W, Hauschild J, Lange T, Venz S, Bauer C, Bähring R, Amann K, Mandanchi R, Schumacher U, Schröder-Schwarz J, Makarieva T, Guzii A, Tabakmakher K, Fedorov S, Shubina L, Kasheverov I, Ehmke H, Steuber T, Stonik V, Bokemeyer C, Honecker F, von Amsberg G
ONCOTARGET. 2016;7(43):69703 - 69717.

Platinum-refractory germ cell tumors
Oing C, Alsdorf W, von Amsberg G, Oechsle K, Bokemeyer C
WORLD J UROL. 2016 [Epub ahead of print].

Intratumoral heterogeneity of KRAS mutation is rare in non-small-cell lung cancer.
Alsdorf W, Clauditz T, Hoenig T, Quaas A, Sirma H, Koenig A, Izbicki J, Sauter G, Marx A, Grob T
EXP MOL PATHOL. 2013;94(1):155-159.

Letzte Aktualisierung aus dem FIS: 17.07.2017 - 00:04 Uhr